Mumbai, May 20 -- Alembic Pharmaceuticals Ltd is expanding its branded speciality drugs portfolio in the US as part of a 'twin engine play' to boost growth in the market as generic pricing pressure continues, chief financial officer G. Krishnan told Mint in an interview.

The drugmaker entered the segment in the fourth quarter of 2025-26, launching Pivya in March to treat uncomplicated urinary tract infections in women.

"We intend to build this as a franchise, so there will be new branded product additions into this franchise," Krishnan said, adding that the company would want to focus on strengthening the women's health segment before expanding into other therapeutic areas.

The entry into branded drugs marks a strategic pivot for the g...